抗凝药对肝硬化合并门静脉血栓患者的害处与益处
该回顾性研究纳入2003至2015年意大利63例因首次发现非肿瘤性门静脉血栓而接受抗凝治疗的肝硬化患者,并与160例无肝硬化的静脉血栓栓塞患者及139例未用维生素K拮抗剂的肝硬化对照比较。结果显示门静脉血栓组大出血与小出血发生率均高于静脉血栓栓塞组,但完全再通与无门静脉高压相关事件生存及无移植生存改善独立相关。
要点
- 门静脉血栓组大出血24%、小出血29%,分别高于静脉血栓栓塞组的7%和19%。
- 门静脉血栓组上消化道大出血率高于静脉血栓栓塞组,其余类型大出血无显著差异。
- 接受维生素K拮抗剂后完全再通与无门静脉高压相关事件生存及无移植生存改善独立相关。
核心结论
- 在63例因门静脉血栓接受抗凝治疗的肝硬化患者回顾分析中,维生素K拮抗剂使用较无肝硬化用维生素K拮抗剂者增加小出血风险,但该风险被再通带来的无门静脉高压相关事件生存及无移植生存改善所抵消。
- 门静脉高压而非抗凝药可能解释门静脉血栓组与静脉血栓栓塞组之间大出血风险的差异。
研究设计与样本
- 意大利2003至2015年回顾性研究,纳入63例因首次发现非肿瘤性门静脉血栓接受抗凝治疗的连续肝硬化患者。
- 对照包括160例无肝硬化静脉血栓栓塞患者(比较出血事件,随访至4年)和139例未接受维生素K拮抗剂的肝硬化患者(分析门静脉高压相关事件)。
- 以基于国际标准化比值的治疗范围内时间评估抗凝质量,并用生存分析比较维生素K拮抗剂效果。
主要发现
- 静脉血栓栓塞组与门静脉血栓组在年龄、性别和治疗范围内时间上可比,但静脉血栓栓塞组接受维生素K拮抗剂时间更长(31.1 ± 16.9个月 vs 23.3 ± 16.2个月;P = .002)。
- 门静脉血栓组大出血或小出血发生率高于静脉血栓栓塞组(大出血24% vs 7%;P = .012;小出血29% vs 19%;P = .024)。
- 门静脉血栓组上消化道大出血率高于静脉血栓栓塞组(P = .019),其他类型大出血无显著差异(P = .376)。
- 门静脉血栓组与对照组上消化道出血率相同。
- 接受维生素K拮抗剂的门静脉血栓患者中完全再通(n = 31)与无门静脉高压相关事件生存及无移植生存时间延长独立相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Vitamin K antagonists (VKAs) promote recanalization of portal vein thrombosis (PVT) in patients with cirrhosis. However, the benefit of PVT recanalization might be offset by major and minor bleeding associated with use of anticoagulants. We evaluated harmful and beneficial effects of VKA in patients with PVT and cirrhosis. METHODS: We performed a retrospective study of 63 consecutive patients with cirrhosis given anticoagulants for the first detection of non-neoplastic PVT from 2003 to 2015 in Italy. We collected data on bleeding events in these patients and compared them with those from patients without cirrhosis with venous thromboembolism (VTE) (n = 160) for up to 4 years. Time in the therapeutic range, based on the international normalized ratio, was used to determine the quality of anticoagulation. We also collected data from 139 patients with cirrhosis who did not receive VKAs (controls), to analyze portal hypertension-related events. We performed survival analyses to determine the effects of VKA in patients with PVT vs controls. RESULTS: The group with VTE and the group with PVT were comparable in age, sex, and time in the therapeutic range, but patients with VTE received VKAs for a longer time period (31.1 ± 16.9 mo vs 23.3 ± 16.2 mo; P = .002). The incidence of major or minor bleeding was higher in patients with PVT than patients with VTE (major, 24% vs 7%; P = .012; minor, 29% vs 19%; P = .024). Patients with PVT had a higher rate of major bleeding from the upper-gastrointestinal tract than patients with VTE (P = .019), but there were no significant differences in other types of major bleeding (P = .376). Patients with PVT and controls had the same rate of upper-gastrointestinal bleeding. Complete recanalization in patients with PVT receiving VKA (n = 31) was independently associated with increased portal hypertension-related event-free and transplantation-free survival times. CONCLUSIONS: In a retrospective analysis of 63 patients with cirrhosis given anticoagulants for PVT, we found VKA use to increase risk of minor bleeding, compared with patients without cirrhosis given VKA. However, this risk is offset by the ability of VKA to increase portal hypertension-related, event-free, and transplantation-free survival of patients with PVT recanalization. Portal hypertension, rather than anticoagulants, could account for the difference in risk of major bleeding between patients with PVT vs patients with VTE.
引用
- La Mura V, Braham S, Tosetti G, et al. Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. Clin Gastroenterol Hepatol. 2017. PMID: 29066371. doi:10.1016/j.cgh.2017.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。